One indication for how important it is for Lympro to be First to Market with their historic AD blood test is Nanosomix's willingness to take their decent science and throw a "Hail Mary." Trying to launch prematurely with only their "case control study" results rather than taking the time to do a more reliable "cohort study" as Lympro went through suggests they are desperate, even willing to risk the reputation of their potentially good science, just so they could ride Lympro's coat tails!

I am more convinced than ever that all these other blood tests that have tried to throw themselves into the public spot light this past year are doing so because they fear they will be rendered irrelevant once LymPro becomes embraced by Pharma....being first to market.

Nanosomix simply has not done the testing necessary for them to withstand the scrutiny required to win over pharmas doing phase 2 and 3 clinical trials!! Lympro has and it has the diagnostic experts on board to garner the confidence of the Alzheimer's industry. Nanosomix partnering with Pan Laboratories who only have a little over a year's experience and a handful of employees is not ready for prime time.

We will soon be hearing of pharmas signing up to use Lympro!